STEDMAN LIMITED

Company number 08923128 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Score: D+ (Critical but Stabilising)

Stedman Limited is receiving a D+ because, while the company is technically solvent and breathing on its own, it is suffering from severe financial atrophy. The business has shrunk drastically over the past seven years, and its equity cushion is dangerously thin. However, the score is elevated slightly from a flat D because the company has successfully shed a significant amount of historical debt and returned to a marginal state of profitability in the latest year. The patient is alive, but severely underweight and lacking the reserves to fight off a sudden financial illness.


Key Vital Signs

  • Net Assets (Equity Cushion): £290
    • Interpretation: This is the company's financial blood pressure, and it is dangerously low. Net assets have plummeted from £11,216 in 2022 to just £290 in 2025. This means that after paying all liabilities, the business has almost zero net worth. A minor unexpected expense could cause internal bleeding (insolvency).
  • Total Assets: £14,289
    • Interpretation: Representing the total body mass of the company, this figure has shrunk from a peak of £110,072 in 2016 to just £14,289 today. This is a classic symptom of a business that is winding down or experiencing severe contraction in its trading activities.
  • Total Liabilities: £12,424
    • Interpretation: The company's financial obligations have dropped significantly from £80,905 in 2018. This is a positive vital sign, indicating that the director has been actively treating and reducing the company's debt burden.
  • Current Ratio (Working Capital Health): 1.15x
    • Interpretation: Calculated as Current Assets (£14,288) divided by Current Liabilities (£12,424). This ratio is like the company's immediate immune system. A ratio above 1.0 means the company can cover its short-term debts, which is healthy, but at 1.15, it has virtually no margin for error.

Diagnosis

Chronic Business Atrophy with Recent Stabilisation

The financial data reveals a business that has undergone a massive contraction. Historically (circa 2016-2018), Stedman Limited operated with a much larger balance sheet, but it was heavily leveraged—liabilities accounted for over 99% of its total assets, leaving it with a paper-thin equity base.

Over the last seven years, the company has experienced severe "muscle wasting." Total assets have declined by over 87% from their 2016 peak. This typically indicates that the business has either lost major contracts, the director has deliberately scaled down operations, or it has ceased active trading in its core market (Combined facilities support activities) and is winding down.

However, there is a silver lining in the most recent vital signs. Between 2024 and 2025, net assets increased from £103 to £290. This means the company generated a small profit (£187) during the year. Furthermore, the director has successfully cured the company's historical over-leverage; the fever of high debt has broken, with total liabilities reduced to manageable levels. The patient is no longer drowning in debt, but it is now incredibly frail. With just £290 in net assets and £1 in fixed assets, the business lacks the financial stamina to withstand any significant external shock.


Recommendations

  1. Financial Blood Transfusion (Capital Injection): With net assets of just £290, the company is one bad month away from insolvency. The director should consider injecting fresh equity into the business to build up a healthy working capital reserve, creating a buffer against unexpected costs or delayed payments from clients.
  2. Avoid Dividend Withdrawals: The company has taken on significant debt in the past and is only now showing a slender profit. All profits should be retained in the business to rebuild the P&L reserve rather than being withdrawn as dividends. The patient needs to keep its nutrients to regain strength.
  3. Lifestyle Review (Strategic Direction): Given the dramatic reduction in the scale of the business, the director needs to conduct a strategic health check. Is the company planning to grow again, or is it in a terminal wind-down phase? If it is no longer actively trading, steps should be taken to formally dissolve the company to avoid ongoing compliance costs. If it intends to trade, a new business plan is required to rebuild asset mass.
  4. Maintain Strict Liquidity Hygiene: With a current ratio of only 1.15, cash flow management must be meticulous. Invoice promptly, chase debts aggressively, and negotiate the longest possible payment terms with suppliers to preserve cash within the business.

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 29 July 2026